Novo Holdings
Novo Holdings, established in 1999 and based in Copenhagen, is the asset manager for the Novo Nordisk Foundation, overseeing its wealth and investments. The company primarily focuses on the life sciences sector, investing across various stages of company development, from early-stage ventures to established firms. Novo Holdings also manages a diversified portfolio of financial investments, including equity and fixed income securities. It is recognized as a leading life science investor globally and aims to generate long-term value to support the Foundation's grant obligations for medical and scientific research. Additionally, it plays a pivotal role in the Novo Group, maintaining a significant influence over its associated companies, including Novo Nordisk and Novozymes, while ensuring compliance with the group’s shared values and management principles. Through initiatives like Novo Seeds, the firm supports early-stage applied research in Scandinavia, further solidifying its commitment to advancing health and welfare through strategic investments.
Engimmune Therapeutics is a biotechnology company focused on developing innovative T cell receptor (TCR) therapies for cancer treatment, particularly targeting solid tumors. The company utilizes advanced technologies, including genome editing, high-throughput screening, deep sequencing, and machine learning, to create highly potent and specific immunotherapies. By addressing critical challenges in efficacy and safety, Engimmune aims to provide effective solutions for patients facing serious diseases with significant unmet medical needs. Through its comprehensive platform, the company is dedicated to advancing the next generation of TCR-based therapies, contributing to the evolving landscape of cancer treatment.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
Sonion A/S design and manufacturing of advanced miniature components and solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.